PCSK9 promotes atherosclerosis progression through the FOXO3a autophagy signaling pathway - Summary - MDSpire

PCSK9 promotes atherosclerosis progression through the FOXO3a autophagy signaling pathway

  • By

  • Yuanjia Shi

  • Jing Zhang

  • Lina Dai

  • Jie Chen

  • Shijia Geng

  • Yan Niu

  • Chongyang Dong

  • Chenlei Li

  • Rujin Liu

  • Ningxia Zhao

  • Xiaomeng Wang

  • Zhanfeng Gao

  • Xi Yang

  • Shang Gao

  • June 15, 2026

  • 0 min

Share

Objective:

To investigate the mechanisms by which PCSK9 influences atherosclerosis through the autophagy pathway.

Approach:
    Key Findings:
    • COS significantly reduced PCSK9 expression and autophagy-related protein expression in macrophages.
    • PCSK9 enhances the expression of autophagy-related proteins and promotes autophagic injury in macrophages.
    • FOXO3a inhibitor JY2 significantly inhibited autophagy but did not significantly affect PCSK9 levels.
    • COS and CQ limited PCSK9 in atherosclerosis progression in both mice and macrophages.
    Interpretation:

    Limitations:
    • The study primarily uses animal models and in vitro systems, which may not fully replicate human atherosclerosis.
    • Further research is needed to explore the clinical implications of these findings.
    Conclusion:

Original Source(s)

PCSK9 promotes atherosclerosis progression through the FOXO3a autophagy signaling pathway

  • by Yuanjia Shi, Jing Zhang, Lina Dai, Jie Chen, Shijia Geng, Yan Niu, Chongyang Dong, Chenlei Li, Rujin Liu, Ningxia Zhao, Xiaomeng Wang, Zhanfeng Gao, Xi Yang, Shang Gao

  • June 15, 2026

Related Content

Does Weight Loss Intervention Improve Persistent AF?

Randomized trial found significant weight loss did not improve atrial fibrillation severity or burden in older patients with persistent disease.

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Impact of the longitudinal evolution of impaired fasting glucose on cardio-kidney-metabolic multimorbidity